全文获取类型
收费全文 | 643篇 |
免费 | 57篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 44篇 |
妇产科学 | 3篇 |
基础医学 | 56篇 |
口腔科学 | 1篇 |
临床医学 | 46篇 |
内科学 | 174篇 |
皮肤病学 | 171篇 |
神经病学 | 68篇 |
特种医学 | 7篇 |
外科学 | 14篇 |
综合类 | 81篇 |
预防医学 | 5篇 |
眼科学 | 5篇 |
药学 | 18篇 |
中国医学 | 5篇 |
肿瘤学 | 12篇 |
出版年
2023年 | 27篇 |
2022年 | 22篇 |
2021年 | 41篇 |
2020年 | 34篇 |
2019年 | 36篇 |
2018年 | 28篇 |
2017年 | 28篇 |
2016年 | 22篇 |
2015年 | 19篇 |
2014年 | 38篇 |
2013年 | 53篇 |
2012年 | 27篇 |
2011年 | 29篇 |
2010年 | 27篇 |
2009年 | 29篇 |
2008年 | 21篇 |
2007年 | 33篇 |
2006年 | 21篇 |
2005年 | 23篇 |
2004年 | 22篇 |
2003年 | 22篇 |
2002年 | 16篇 |
2001年 | 17篇 |
2000年 | 12篇 |
1999年 | 6篇 |
1998年 | 4篇 |
1997年 | 7篇 |
1996年 | 3篇 |
1995年 | 6篇 |
1994年 | 6篇 |
1993年 | 7篇 |
1992年 | 6篇 |
1991年 | 3篇 |
1989年 | 4篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 4篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
排序方式: 共有711条查询结果,搜索用时 20 毫秒
1.
Hitoshi Kohsaka Tsuneyo Mimori Takashi Kanda Jun Shimizu Yoshihide Sunada Manabu Fujimoto Yasushi Kawaguchi Masatoshi Jinnin Yoshinao Muro Shoichiro Ishihara Hiroyuki Tomimitsu Akiko Ohta Takayuki Sumida 《The Journal of dermatology》2019,46(1):e1-e18
Although rheumatologists, neurologists and dermatologists see patients with polymyositis (PM) and dermatomyositis (DM), their management appears to vary depending on the physician's specialty. The aim of the present study was to establish the treatment consensus among specialists of the three fields to standardize the patient care. We formed a research team supported by a grant from the Ministry of Health, Labor and Welfare, Japan. Clinical questions (CQ) on the management of PM and DM were raised. A published work search on CQ was performed primarily using PubMed. Using the nominal group technique, qualified studies and results in the published work were evaluated and discussed to reach consensus recommendations. They were sent out to the Japan College of Rheumatology, Japanese Society of Neurology and Japanese Dermatological Association for their approval. We reached a consensus in 23 CQ and made recommendations and a decision tree for management was proposed. They were officially approved by the three scientific societies. In conclusion, a multidisciplinary treatment consensus for the management of PM and DM was established for the first time. 相似文献
2.
3.
4.
Risa Konishi Ryota Tanaka Sae Inoue Yuki Ichimura Toshifumi Nomura Naoko Okiyama 《The Journal of dermatology》2022,49(1):118-123
Dermatomyositis, an idiopathic inflammatory myopathy, is characterized by cutaneous itchy manifestations, which are frequently refractory and recurrent even after intensive immunosuppressive treatments. To evaluate the effectiveness and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in treating skin-dominant dermatomyositis in which myositis and interstitial lung disease are absent or in remission, we performed this prospective, single-arm, interventional study. A total of five Japanese patients (one male and four females, median [range] age, 64 [37–71] years) with refractory dermatomyositis-associated cutaneous manifestations were recruited and treated with a 12-week course of oral apremilast. Among five enrolled patients, three experienced diarrhea with full-dose apremilast (30 mg twice daily), two of whom withdrew from the study and recovered quickly afterwards. A total of three evaluable female patients (median [range] age, 65 [64–71] years) received apremilast treatment for 12 weeks. A 39.4% reduction from baseline Cutaneous Dermatomyositis Disease Area and Severity Index total activity score, but not the damage score, at week 12 was observed in all three patients. Visual analog scale of itching, and quality of life by Dermatology Life Quality Index were slightly improved in one and two apremilast-treated patients, respectively. As apremilast was effective, with expected and recoverable digestive adverse events (diarrhea), in patients with refractory and recurrent dermatomyositis-associated cutaneous manifestations in this first phase Ib study, it can be suggested as a possible treatment when aggressive immunosuppressive therapies with high-dose systemic corticosteroid and/or immunosuppressive agents for other manifestations, myositis, and interstitial lung disease, are not required. 相似文献
5.
Manabu Fujimoto Jun Asai Yoshihide Asano Takayuki Ishii Yohei Iwata Tamihiro Kawakami Masanari Kodera Masatoshi Abe Masahiro Amano Ryuta Ikegami Taiki Isei Zenzo Isogai Takaaki Ito Yuji Inoue Ryokichi Irisawa Masaki Ohtsuka Yoichi Omoto Hiroshi Kato Takafumi Kadono Sakae Kaneko Hiroyuki Kanoh Masakazu Kawaguchi Ryuichi Kukino Takeshi Kono Monji Koga Keisuke Sakai Eiichi Sakurai Yasuko Sarayama Yoichi Shintani Miki Tanioka Hideaki Tanizaki Jun Tsujita Naotaka Doi Takeshi Nakanishi Akira Hashimoto Minoru Hasegawa Masahiro Hayashi Kuninori Hirosaki Hideki Fujita Hiroshi Fujiwara Takeo Maekawa Koma Matsuo Naoki Madokoro Sei-Ichiro Motegi Hiroshi Yatsushiro Osamu Yamasaki Yuichiro Yoshino Andres James LE Pavoux Takao Tachibana Hironobu Ihn Japanese Dermatological Association Guidelines 《The Journal of dermatology》2020,47(10):1071-1109
The Japanese Dermatological Association prepared guidelines focused on the treatment of skin ulcers associated with connective tissue disease/vasculitis practical in clinical settings of dermatological care. Skin ulcers associated with connective tissue diseases or vasculitis occur on the background of a wide variety of diseases including, typically, systemic sclerosis but also systemic lupus erythematosus (SLE), dermatomyositis, rheumatoid arthritis (RA), various vasculitides and antiphospholipid antibody syndrome (APS). Therefore, in preparing the present guidelines, we considered diagnostic/therapeutic approaches appropriate for each of these disorders to be necessary and developed algorithms and clinical questions for systemic sclerosis, SLE, dermatomyositis, RA, vasculitis and APS. 相似文献
6.
7.
8.
Dermatomyositis paraneoplastic syndrome before symptomatic tonsillar squamous cell carcinoma: A case report 下载免费PDF全文
9.
《Paediatrics & Child Health》2014,24(5):215-220
Juvenile dermatomyositis is the most common idiopathic inflammatory myopathy of childhood. Management focuses on early aggressive suppression of inflammation to induce sustained remission and prevent complications such as muscle contractures or calcinosis. Advances in diagnostic modalities and treatment have led to improved mortality and morbidity, but long-term risks remain significant. Early disease recognition with appropriate referral and management by a specialist multidisciplinary team is crucial. This review focuses on juvenile dermatomyositis including differential diagnosis from other conditions causing muscle weakness in children. 相似文献
10.